Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

Journal of Neuro-oncology
V A LevinM Baillet

Abstract

Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas. A total of 162 patients with intracranial glioblastoma multiforme or gliosarcomas who had undergone surgery and radiotherapy participated in this multicenter, double-blind, placebo-controlled, parallel group study conducted at 20 institutions. Seventy-nine patients (57 male, 22 female, median age 58 years) were randomized to receive placebo (PB), and 83 patients (51 male, 32 female, median age 57 years) were randomized to receive MT, 10 mg orally twice daily, until tumor progression. This intention-to-treat efficacy analysis showed no statistically significant difference between MT and PB groups with respect to survival (P = 0.38, log rank test). The median survival time from protocol initiation was 37.9 weeks for the PB group and 42.9 weeks for the MT group, with a hazard ratio of 1.16 (95% CI 0.83 to 1.60). There were no statistically significant differences in quality of life between the PB and MT groups, as assessed by the FACT-BR questionnaire. Musculoskeletal toxicities led to dose modification or withd...Continue Reading

References

Sep 1, 1977·Journal of Neurosurgery·V A LevinC B Wilson
May 1, 1974·Clinical Pharmacology and Therapeutics·D R Taves
Jan 1, 1995·Advances in Enzyme Regulation·P D Brown
Jan 1, 1996·Journal of Neurosurgery·M A WeitznerK Byrne
Dec 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P D Brown, R Giavazzi
Oct 3, 1999·The Journal of Biological Chemistry·M S O'ReillyM A Moses
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D OsobaM Prados
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Morris D GrovesVictor A Levin
Mar 30, 2002·Science·Lisa M CoussensLynn M Matrisian
Sep 5, 2002·Nature Reviews. Cancer·Christopher Mark Overall, Carlos López-Otín
Jul 2, 2003·Nature Reviews. Cancer·Jasti S Rao

❮ Previous
Next ❯

Citations

Sep 1, 2007·Anti-cancer Drugs·Riccardo SoffiettiElisa Trevisan
Aug 4, 2011·Nature Reviews. Neuroscience·Manfred Westphal, Katrin Lamszus
Mar 24, 2020·The Cochrane Database of Systematic Reviews·Catherine HannaRobin Grant
May 12, 2007·Expert Review of Anticancer Therapy·Marta Penas-Prado, Mark R Gilbert
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·V Wee YongDavid P Stirling
Jan 21, 2012·European Neurology·Fredrik RomiNils Erik Gilhus
Jul 26, 2012·Journal of Signal Transduction·Valentina CeaChiara Verpelli
Feb 11, 2014·Current Oncology Reports·Mohamed Ali Hamza, Mark Gilbert
Jul 19, 2014·Neurological Research·Danop NanegrungsunkSiriporn C Chattipakorn
Jul 17, 2008·Neuro-oncology·Jin-xiang ChengBo-Lin Liu
Nov 21, 2007·Expert Review of Anticancer Therapy·Andrew ChiPatrick Y Wen
Jan 12, 2011·Brain Tumor Pathology·Manabu OnishiIsao Date
Feb 7, 2013·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Patrick N HarterMichel Mittelbronn
Feb 1, 2012·The Cancer Journal·Jethro Hu, Santosh Kesari
Apr 7, 2009·Expert Review of Neurotherapeutics·Jan DrappatzPatrick Y Wen
Sep 27, 2013·Cell Cycle·Jennifer MunsonRavi Bellamkonda
Sep 1, 2008·Expert Opinion on Medical Diagnostics·Pia VihinenVeli-Matti Kähäri
Aug 3, 2014·Neuro-oncology·Jin LanYongming Qiu
Oct 26, 2016·Integrative Biology : Quantitative Biosciences From Nano to Macro·Kathryn M KingsmoreJennifer M Munson
Feb 22, 2012·Journal of Neuro-oncology·A TalacchiM Gerosa
Dec 1, 2006·Expert Review of Anticancer Therapy·Lijo Simpson, Evanthia Galanis
Jun 27, 2009·Expert Opinion on Investigational Drugs·Cory AdamsonDarell D Bigner
Nov 16, 2011·Clinical Medicine Insights. Oncology·Manuel Nieto-SampedroManuel Nieto-Díaz
Jan 14, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Nancy WangTracy T Batchelor
Nov 29, 2007·Expert Opinion on Investigational Drugs·Elizabeth R GerstnerTracy T Batchelor
May 15, 2013·Current Neurology and Neuroscience Reports·Linda DirvenMartin J B Taphoorn
Dec 21, 2006·Cancer Research·Susobhan SarkarV Wee Yong
Nov 18, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mohan S NandhuMariano S Viapiano
Sep 25, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tony AvrilVéronique Quillien
May 8, 2018·Molecular Cancer Therapeutics·Arthur WinerPaolo Mignatti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.